

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5782275

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
KEITH JONES	08/06/2015
CARL RYE	09/21/2015
NICOLA CHESSUM	08/06/2015
MATTHEW D. CHEESEMAN	08/06/2015
A. E. PASQUA	08/06/2015
RECEIVING PARTY DATA	
Name:	CANCER RESEARCH TECHNOLOGY LIMITED
Street Address:	ANGEL BUILDING
Internal Address:	407 ST JOHN STREET
City:	LONDON
State/Country:	UNITED KINGDOM
Postal Code:	EC1V 4AD
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16212455
CORRESPONDENCE DATA	
Fax Number:	(617)832-7000
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 832-1786
Email:	patentdocketing@foleyhoag.com, kdunn@foleyhoag.com
Correspondent Name:	FOLEY HOAG LLP
Address Line 1:	155 SEAPORT BOULEVARD
Address Line 4:	BOSTON, MASSACHUSETTS 02210-2600
ATTORNEY DOCKET NUMBER:	HGX-02303
NAME OF SUBMITTER:	KATHRYN DUNN
SIGNATURE:	/Kathryn Dunn/
DATE SIGNED:	10/22/2019
Total Attachments: 6	

source=HGX-02302_3_Assignment_Inventors_to_CRTL#page1.tif
source=HGX-02302_3_Assignment_Inventors_to_CRTL#page2.tif
source=HGX-02302_3_Assignment_Inventors_to_CRTL#page3.tif
source=HGX-02302_3_Assignment_Inventors_to_CRTL#page4.tif
source=HGX-02302_3_Assignment_Inventors_to_CRTL#page5.tif
source=HGX-02302_3_Assignment_Inventors_to_CRTL#page6.tif

**ASSIGNMENT OF INVENTION
AND RELATED INTELLECTUAL PROPERTY RIGHTS**

Parties:

1 'The Inventors'

Keith Jones

of the Institute of Cancer Research, 15 Costwolds Road, Sutton, Surrey SM2 5NG,
United Kingdom

Carl Rye

of the Institute of Cancer Research, 15 Costwolds Road, Sutton, Surrey SM2 5NG,
United Kingdom

Nicola Chessum

of the Institute of Cancer Research, 15 Costwolds Road, Sutton, Surrey SM2 5NG,
United Kingdom

Matthew Cheeseman

of the Institute of Cancer Research, 15 Costwolds Road, Sutton, Surrey SM2 5NG,
United Kingdom

Elisa Adele Pasqua

of the Institute of Cancer Research, 15 Costwolds Road, Sutton, Surrey SM2 5NG,
United Kingdom

2 'Employer'

THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
of 123 Old Brompton Road, London SW7 3RP, United Kingdom

3 'Assignee'

CANCER RESEARCH TECHNOLOGY LIMITED

of Angel Building, 407 St John Street, London, EC1V 4AD, United Kingdom

Recitals:

(A) The Inventors are the joint inventors of the invention entitled *FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1* (the "**Invention**") for which the United Kingdom Patent Application ("the Priority Application") and the international patent applications claiming priority from the Priority Application (the "**PCT Application**") set forth in the schedule hereto have been filed; and

(B) The Inventors were at all relevant times employees of Employer and for the purposes of commercial exploitation the Inventors and Employer (the "Assignors") have agreed to assign to the Assignee for the consideration hereinafter mentioned any and all rights title and interest they may have in to and under the Invention, the Priority Application and the PCT Application and all national and regional patent applications derived therefrom and any and all other applications linked by priority thereto.

Operative provisions:

In consideration for the payment of one pound (£1.00) by the Assignee to the Assignors, the receipt and sufficiency of which is hereby acknowledged by the Assignors:

1 The Assignors hereby assign to the Assignee absolutely and free from encumbrances:

1.1 all their respective rights title and interest in all countries of the world in to and under the Invention, the Priority Application and the PCT Application and all national and regional patent applications derived therefrom and any and all other applications linked by priority thereto and any and all divisionals, continuations and continuations-in-part of any of the aforesaid applications and any and all patents that may be granted pursuant thereto for the full period thereof including any re-issues, re-examinations, renewals, extensions and Supplementary Protection Certificates and including all rights and powers arising or accrued therefrom including the right to sue for damages and other remedies in respect of any infringement of any such rights before on or after the date hereof and to retain any damages obtained as a result of such action;

1.2 all such rights as they may have to apply for prosecute and obtain patents and other intellectual property protection anywhere in the world in respect of the Invention to the intent that the grant of any patents or other intellectual property protection for the Invention shall be in the name of and shall vest in the Assignee or their successors or assigns; and

1.3 all such rights as they may have to claim priority from the Priority Application in any and all applications for patent protection for the Invention, such rights to be enjoyed by the Assignee with effect from the date of filing of the Priority Application;

to the intent that the Assignee shall have and hold the rights title and interest hereby assigned as fully and entirely as the same would have been held and enjoyed by the Assignors had this assignment not been made.

2 The Assignors hereby GRANT the Assignee the power to insert in the Schedule to this assignment any further identification of any patent applications in any countries or regions of the world which fall within the scope of clause 1 above, as may be necessary or desirable in order to comply with the rules of the any Patent Office for recordation of this document.

3 The Assignors hereby UNDERTAKE that at the request and cost of the Assignee or its successors or assigns they will at all times hereafter promptly do all such acts and execute all such documents (including but not limited to documents required to be signed by or on behalf of inventors in the course of any and all Canadian and United States patent applications which relate to the Invention and any and all divisionals, continuations and continuations-in-part of any such applications) as may be reasonably necessary or desirable to secure the vesting in the Assignee or its successors or assigns of all rights title and interest assigned to the Assignee hereunder and to confirm the title of the Assignee or its successors or assigns to all such rights title and interest and to assist in the resolution of any question concerning the Invention or any Applications for patent or other intellectual property protection for the Invention or any intellectual property protection granted pursuant to any such application.

4 The Assignors hereby request the relevant authorities in all countries of the world to issue any patents granted for the Invention in the name of the Assignee or its successors or assigns in accordance with this assignment.

5 The Assignors give no warranty and make no representation whatsoever in relation to the Invention and/or the rights assigned hereunder.

6 This assignment and undertaking shall be binding upon the heirs, executors, administrators, successors and/or assigns of the Assignors and shall enure to the benefit of any heirs, executors, administrators, successors and/or assigns of the Assignee.

7 This assignment shall be governed by English law and the parties hereby submit to the exclusive jurisdiction of the courts of England.

8 This assignment may be executed in any one or more number of counterpart assignments each of which, when executed, shall be deemed to form part of and together constitute this assignment


IN WITNESS WHEREOF the parties hereto have executed this assignment and undertaking


SCHEDULE

The Priority Application and the PCT Application

COUNTRY	APPLN No.	FILING DATE
UK	GB 1317609.4	4 October 2013
PCT	PCT/GB2014/052992 (Publication number WO2015/049535)	3 October 2014 (Publication date 9 April 2015)

SIGNED by Keith Jones)
 on: 06/08, 2015)
 in the presence of:)

Signature: 


Witness
 Signature: 
 Name: Y. M. HANCOCK
 Address: 6 THE DRIFTWAY
 BANSTED
 SM7 1LX


SIGNED by Carl Rye)
 on: , 2015)
 in the presence of:)

Signature:


Witness
 Signature:
 Name:
 Address:


SIGNED by Nicola Chessum)
 on: 06/08, 2015)
 in the presence of:)

Signature: 

Witness
 Signature: 
 Name: Y. M. HANCOCK
 Address: 6 THE DRIFTWAY
 BANSTED
 SM7 1LX

SIGNED by Matthew Cheeseman)
 on: 6/8/1, 2015)
 in the presence of:)

Signature: 

Witness
 Signature: 
 Name: Y. M. HANCOCK
 Address: 6 THE DRIFTWAY
 BANSTED
 SM7 1LX

SIGNED by Elisa Adele Pasqua

on: 06/08/2015, 2015

in the presence of:

Witness

Signature:

Name:

Address:

SIGNED by THE INSTITUTE OF CANCER

RESEARCH: ROYAL CANCER HOSPITAL

on: 06 AUG 2015, 2015

SIGNED by CANCER RESEARCH

TECHNOLOGY LIMITED

on: 11 August, 2015

) Signature: Elisa Adele Pasqua

)

) Signature: [Signature]
) Name: STEVE SURROUSE
) Position: DIRECTOR OF OPERATIONS

) Signature: [Signature]
) Name: P J L'Hanrier
) Position: Director: Business Management

IN WITNESS WHEREOF the parties hereto have executed this assignment and undertaking

SCHEDULE


The Priority Application and the PCT Application

COUNTRY	APPLN No.	FILING DATE
UK	GB 1317609.4	4 October 2013
PCT	PCT/GB2014/052992 (Publication number WO2015/049535)	3 October 2014 (Publication date 9 April 2015)

SIGNED by **Keith Jones**)
 on:, 2015) Signature:
 in the presence of:)

Witness
 Signature:
 Name:
 Address:

SIGNED by **Carl Rye**)
 on: 21/09/2015, 2015) Signature: 
 in the presence of:)

Witness
 Signature: 
 Name: ANGELA RYE
 Address: LA CITEAU LE GRENIER, COMMUNY, 1291, SWITZERLAND

SIGNED by **Nicola Chessum**)
 on:, 2015) Signature:
 in the presence of:)

Witness
 Signature:
 Name:
 Address:

SIGNED by **Matthew Cheeseman**)
 on:, 2015) Signature:
 in the presence of:)

Witness
 Signature:
 Name:
 Address: